Intellectual disability-hypotonic facies syndrome, X-linked 1

Mendelian MONDO:0010663 Pathograph 19 Show in embeddings browser X-linked intellectual disability syndrome ATRX-related disorder

ATR-X syndrome (alpha-thalassemia X-linked intellectual disability syndrome; X-linked intellectual disability-hypotonic facies syndrome type 1) is a rare X-linked recessive neurodevelopmental disorder of hemizygous males caused by hypomorphic germline variants in ATRX (Xq21.1), which encodes a SNF2-family chromatin-remodeling ATPase. ATRX cooperates with DAXX to deposit the histone variant H3.3 at heterochromatic and repetitive regions and contributes to transcriptional regulation, DNA-damage repair, and heterochromatin maintenance. Loss of ATRX function produces mild-to-profound intellectual disability, distinctive craniofacial features, hypotonia, genital/genitourinary anomalies, gastrointestinal complications, skeletal abnormalities, and (in about 75% of individuals) alpha-thalassemia with hemoglobin H (HbH) inclusions. Most pathogenic variants are missense changes clustered in the ADD and helicase/ATPase domains; complete null alleles are not found in patients, consistent with embryonic lethality of full ATRX deletion in mice.

Ask OpenScientist

Ask a research question about Intellectual disability-hypotonic facies syndrome, X-linked 1. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
1
Pathophys.
17
Phenotypes
1
Hypotheses
19
Pathograph
1
Genes
3
Medical Actions
1
References
1
Deep Research
👪

Inheritance

1
X-linked recessive HP:0001419
ATR-X syndrome is inherited in an X-linked manner. Hemizygous males are affected; the mother of a proband may be a heterozygous carrier or the affected individual may have a de novo pathogenic variant. Female carriers rarely show clinical manifestations, in part due to skewed X-inactivation.
X-linked recessive inheritance
Show evidence (2 references)
PMID:20301622 SUPPORT Human Clinical
"ATR-X syndrome is inherited in an X-linked manner."
GeneReviews establishes X-linked inheritance for ATR-X syndrome.
PMID:20301622 SUPPORT Human Clinical
"sibs with a 46,XX karyotype who inherit the pathogenic variant will be heterozygous and will rarely show clinical manifestations."
Confirms that female carriers rarely manifest, consistent with X-linked recessive inheritance.
◈

Mechanistic Hypotheses

1
Canonical ATRX Chromatin-Remodeling Loss-of-Function Model
canonical_atrx_chromatin_remodeling_loss CANONICAL
Hypomorphic germline ATRX variants (most commonly missense changes in the ADD and helicase/ATPase domains) impair the function of a SNF2-family chromatin-remodeling ATPase. ATRX normally partners with DAXX to deposit histone variant H3.3 at heterochromatin and repetitive/telomeric regions and to maintain heterochromatin, regulate transcription, and support DNA-damage/replication-stress responses. Loss of ATRX recruitment to heterochromatin (mediated by ADD-domain binding to H3K9me3) dysregulates transcription and genome stability, producing the neurodevelopmental and multisystem phenotype, including alpha-thalassemia via downregulation of the alpha-globin locus.
Show evidence (2 references)
PMID:37171606 SUPPORT Model Organism
"ATRX is a chromatin remodelling ATPase that is involved in transcriptional regulation, DNA damage repair and heterochromatin maintenance."
Defines the canonical molecular functions of ATRX that are lost in ATR-X syndrome.
PMID:37190157 SUPPORT Other
"chromatin remodeling protein that primarily promotes the deposit of H3.3 histone variants in the telomere area."
Establishes the ATRX/H3.3 chromatin-deposition mechanism underlying the disorder.
⚙

Pathophysiology

1
ATRX chromatin-remodeling loss of function
Hypomorphic ATRX variants disrupt the chromatin-remodeling ATPase activity of ATRX and its ADD-domain-mediated recruitment to H3K9me3-marked heterochromatin. With DAXX, ATRX deposits the histone variant H3.3 at telomeric and pericentromeric heterochromatin; loss of this activity impairs heterochromatin maintenance, transcriptional regulation, and genome stability, driving the neurodevelopmental and multisystem manifestations.
Neuron CL:0000540
ATRX hgnc:886
Chromatin remodeling GO:0006338 ↓ DECREASED Heterochromatin organization GO:0070828 ↓ DECREASED H3.3 nucleosome assembly GO:0006334 ↓ DECREASED Regulation of transcription GO:0006355 ⚠ ABNORMAL DNA repair GO:0006281 ⚠ ABNORMAL
Downstream
Intellectual disability
Distinctive craniofacial features
Telecanthus
Hypotonia
Genital anomalies
Hypospadias
Alpha-thalassemia with HbH inclusions
Seizures
Behavioral abnormality
Congenital heart defect
Gastrointestinal dysmotility
Gastroesophageal reflux
Drooling
Skeletal abnormality
Short stature
Microcephaly
Osteosarcoma
Show evidence (2 references)
PMID:37171606 SUPPORT Model Organism
"carrying the most common causative mutation, R246C. This is one of a cluster of missense mutations located in the chromatin-binding domain and disrupts its function."
The patient-mutation knock-in mouse demonstrates that the common R246C variant lies in the chromatin-binding domain and disrupts its function, the core molecular lesion of ATR-X syndrome.
PMID:39479502 SUPPORT Other
"These mutations disrupt the organization, subcellular localization, and transcriptional activity of ATRX, leading to chromosomal instability and affecting interactions with key regulatory proteins such as DAXX, EZH2, and TERRA."
Establishes that ATRX mutations impair its organization, localization, transcriptional activity, and DAXX interaction, producing chromosomal instability.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Intellectual disability-hypotonic facies syndrome, X-linked 1 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

17
Cardiovascular 1
Congenital heart defect OCCASIONAL Abnormal heart morphology HP:0001627
Show evidence (1 reference)
PMID:39363269 SUPPORT Human Clinical
"Epilepsy, congenital heart disease, urogenital defect, acoustic defect, and optical defect are more prevalent in patients with frameshift mutations compared to those with missense mutations."
Wang et al. 2024 reports congenital heart disease among recurrent manifestations (8/43, 18.60% in their cohort), supporting an OCCASIONAL frequency band.
Digestive 2
Gastrointestinal dysmotility FREQUENT Constipation HP:0002019
Show evidence (1 reference)
PMID:39741769 SUPPORT Human Clinical
"significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux"
Comisi et al. 2024 documents the GI complication spectrum, including chronic constipation.
Gastroesophageal reflux Gastroesophageal reflux HP:0002020
Show evidence (1 reference)
PMID:39741769 SUPPORT Human Clinical
"gastroesophageal reflux, and mild-to-moderate anemia secondary to alpha-thalassemia."
Comisi et al. 2024 lists gastroesophageal reflux among the GI complications.
Genitourinary 1
Hypospadias Hypospadias HP:0000047
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"hypospadias and undescended testicles"
GeneReviews lists hypospadias among the genital anomalies.
Head and Neck 3
Distinctive craniofacial features VERY_FREQUENT Abnormal facial shape HP:0001999
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip with coarsening of the facial features over time."
GeneReviews describes the distinctive craniofacial phenotype of ATR-X syndrome.
Drooling Drooling HP:0002307
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"excessive drooling, and genital anomalies are managed per standard of care."
GeneReviews lists excessive drooling among the manifestations managed in ATR-X syndrome.
Microcephaly Microcephaly HP:0000252
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"small head circumference"
The ATR-X GeneReviews lists small head circumference (microcephaly) among the craniofacial abnormalities of the syndrome.
Musculoskeletal 2
Hypotonia VERY_FREQUENT Hypotonia HP:0001252
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."
GeneReviews lists hypotonia as a characteristic feature.
Osteosarcoma Osteosarcoma HP:0002669
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Osteosarcoma has been reported in"
The ATR-X GeneReviews reports osteosarcoma in a few males with germline ATRX pathogenic variants.
Nervous System 3
Intellectual disability VERY_FREQUENT Intellectual disability HP:0001249
Show evidence (2 references)
PMID:20301622 SUPPORT Human Clinical
"mild-to-profound developmental delay / intellectual disability (DD/ID)."
GeneReviews lists mild-to-profound DD/ID as a core feature.
PMID:39363269 SUPPORT Human Clinical
"mild-to-profound intellectual disability"
Wang et al. 2024 lists mild-to-profound intellectual disability among the core manifestations; in their cohort (Table 1, attached image) intellectual disability was present in 43/43 patients (100%), supporting a VERY_FREQUENT frequency band.
Artifact: image-1.png
image-1.png
Seizures OCCASIONAL Seizure HP:0001250
Show evidence (2 references)
PMID:20301622 SUPPORT Human Clinical
"DD/ID, seizures, gastrointestinal manifestations and feeding difficulties"
GeneReviews lists seizures among the manifestations managed in ATR-X syndrome.
PMID:39363269 SUPPORT Human Clinical
"Epilepsy, congenital heart disease, urogenital defect, acoustic defect, and optical defect are more prevalent in patients with frameshift mutations compared to those with missense mutations."
Wang et al. 2024 reports epilepsy among recurrent manifestations (10/43, 23.26% in their cohort), more prevalent with frameshift than missense variants; supports an OCCASIONAL band.
Behavioral abnormality Autistic behavior HP:0000729
Show evidence (1 reference)
PMID:39363269 SUPPORT Human Clinical
"typical facial abnormalities, urogenital defect, behavior problems, and optical nerve dysplasia."
Wang et al. 2024 reports behavior problems in the proband; autism/behavioral problems were a recurrent feature in their cohort (19/43, 44.19%).
Growth 1
Short stature Short stature HP:0004322
Show evidence (1 reference)
PMID:37171606 SUPPORT Model Organism
"Clinical features also include facial dysmorphism, microcephaly, short stature, musculoskeletal defects and genital abnormalities."
Tillotson et al. 2023, a patient-mutation knock-in mouse model of ATR-X syndrome, lists short stature among the human clinical features the model recapitulates.
Other 4
Telecanthus Telecanthus HP:0000506
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"telecanthus or widely spaced eyes"
GeneReviews lists telecanthus among the craniofacial abnormalities.
Genital anomalies FREQUENT Abnormal male external genitalia morphology HP:0000032
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"genital anomalies comprise a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia, to normal-appearing female external genitalia."
GeneReviews describes the spectrum of genital/genitourinary anomalies in 46,XY males.
Alpha-thalassemia with HbH inclusions FREQUENT HbH hemoglobin HP:0011903
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"Alpha-thalassemia, observed in about 75% of affected individuals, is mild and typically does not require treatment."
GeneReviews documents alpha-thalassemia in about 75% of individuals, supporting a FREQUENT band (the Wang et al. 2024 cohort reported 18/43, 41.86%, confirming it is common but not universal).
Skeletal abnormality FREQUENT Abnormal skeletal morphology HP:0011842
Show evidence (1 reference)
PMID:36292677 SUPPORT Human Clinical
"characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features."
Vaisfeld et al. 2022 lists skeletal anomalies among the characteristic features.
🧬

Genetic Associations

1
ATRX pathogenic variants
Gene: ATRX hgnc:886
Show evidence (3 references)
PMID:39363269 SUPPORT Human Clinical
"are caused by pathogenic variant in the ATRX gene, a member of the switch/sucrose non-fermentable (SWI-SNF) protein family that exhibits chromatin remodeling activity."
Identifies ATRX as the causal SWI/SNF chromatin-remodeling gene.
PMID:39363269 SUPPORT Human Clinical
"Missense mutation is the most common variation type. The ADD and helicase-like domains are the most frequently affected domains."
Establishes the variant-type spectrum and most frequently affected protein domains.
PMID:37171606 SUPPORT Model Organism
"Given that null alleles are not found in patients"
Confirms that pathogenic ATRX alleles in patients are hypomorphic rather than null.
💊

Medical Actions

3
Genetic counseling
Action: Genetic Counseling NCIT:C15240
ATR-X syndrome is inherited in an X-linked manner; genetic counseling addresses carrier testing for at-risk females, prenatal testing, and preimplantation genetic testing once the family ATRX variant is identified.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"carrier testing for at-risk females, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible."
GeneReviews recommends genetic counseling and family-based genetic testing options.
Supportive and symptom-directed care
Action: supportive care MAXO:0000950
No disease-modifying therapy is established; management is supportive and phenotype-driven, including standard-of-care management of DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies.
Show evidence (1 reference)
PMID:20301622 SUPPORT Human Clinical
"DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."
GeneReviews describes supportive, standard-of-care management of manifestations.
Pyridostigmine for gastrointestinal dysmotility
Action: Pharmacotherapy NCIT:C15986
Agent: pyridostigmine CHEBI:8665
Pyridostigmine, an acetylcholinesterase inhibitor / gastrointestinal motility agent, has been used off-label for severe GI dysmotility in ATR-X syndrome. In a reported case, sustained treatment led to full resolution of gastrointestinal symptoms, with favorable pediatric tolerability.
Show evidence (1 reference)
PMID:39741769 SUPPORT Human Clinical
"We report a patient with ATR-X syndrome suffering from gastrointestinal dysmotility and highlight the beneficial effects of pyridostigmine."
Comisi et al. 2024 reports pyridostigmine as a therapeutic option for GI dysmotility in ATR-X syndrome.
{ }

Source YAML

click to show 
name: Intellectual disability-hypotonic facies syndrome, X-linked 1
creation_date: "2026-06-03T00:00:00Z"
category: Mendelian
description: >
  ATR-X syndrome (alpha-thalassemia X-linked intellectual disability syndrome; X-linked
  intellectual disability-hypotonic facies syndrome type 1) is a rare X-linked recessive
  neurodevelopmental disorder of hemizygous males caused by hypomorphic germline variants
  in ATRX (Xq21.1), which encodes a SNF2-family chromatin-remodeling ATPase. ATRX cooperates
  with DAXX to deposit the histone variant H3.3 at heterochromatic and repetitive regions
  and contributes to transcriptional regulation, DNA-damage repair, and heterochromatin
  maintenance. Loss of ATRX function produces mild-to-profound intellectual disability,
  distinctive craniofacial features, hypotonia, genital/genitourinary anomalies,
  gastrointestinal complications, skeletal abnormalities, and (in about 75% of individuals)
  alpha-thalassemia with hemoglobin H (HbH) inclusions. Most pathogenic variants are missense
  changes clustered in the ADD and helicase/ATPase domains; complete null alleles are not
  found in patients, consistent with embryonic lethality of full ATRX deletion in mice.
disease_term:
  preferred_term: ATR-X syndrome
  term:
    id: MONDO:0010663
    label: intellectual disability-hypotonic facies syndrome, X-linked, 1
parents:
- X-linked intellectual disability syndrome
- ATRX-related disorder
references:
- reference: PMID:20301622
  title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
  tags:
  - GeneReviews
inheritance:
- name: X-linked recessive
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  description: >
    ATR-X syndrome is inherited in an X-linked manner. Hemizygous males are affected; the
    mother of a proband may be a heterozygous carrier or the affected individual may have a
    de novo pathogenic variant. Female carriers rarely show clinical manifestations, in part
    due to skewed X-inactivation.
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ATR-X syndrome is inherited in an X-linked manner."
    explanation: GeneReviews establishes X-linked inheritance for ATR-X syndrome.
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sibs with a 46,XX karyotype who inherit the pathogenic variant will be \nheterozygous and will rarely show clinical manifestations."
    explanation: Confirms that female carriers rarely manifest, consistent with X-linked recessive inheritance.
prevalence:
- population: Male newborns
  notes: >-
    A 2024 case report and genotype-phenotype review describes ATR-X syndrome as a rare X-linked
    disorder with a broad multisystem clinical spectrum; worldwide prevalence is reported as
    unknown.
  evidence:
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These \nsyndromes show a wide spectrum of clinical \nmanifestations, such as distinctive dysmorphic features, mild-to-profound \nintellectual disability, motor development delay, seizures, urogenital \nabnormalities, and gastrointestinal disorders."
    explanation: Wang et al. 2024 characterizes ATR-X / MRXHF1 as a rare X-linked disorder with a broad multisystem spectrum.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_atrx_chromatin_remodeling_loss
  hypothesis_label: Canonical ATRX Chromatin-Remodeling Loss-of-Function Model
  status: CANONICAL
  description: >-
    Hypomorphic germline ATRX variants (most commonly missense changes in the ADD and
    helicase/ATPase domains) impair the function of a SNF2-family chromatin-remodeling ATPase.
    ATRX normally partners with DAXX to deposit histone variant H3.3 at heterochromatin and
    repetitive/telomeric regions and to maintain heterochromatin, regulate transcription, and
    support DNA-damage/replication-stress responses. Loss of ATRX recruitment to heterochromatin
    (mediated by ADD-domain binding to H3K9me3) dysregulates transcription and genome stability,
    producing the neurodevelopmental and multisystem phenotype, including alpha-thalassemia via
    downregulation of the alpha-globin locus.
  evidence:
  - reference: PMID:37171606
    reference_title: "A new mouse model of ATR-X syndrome carrying a common patient mutation exhibits neurological and morphological defects."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "ATRX is a chromatin remodelling ATPase that is involved in transcriptional \nregulation, DNA damage repair and heterochromatin maintenance."
    explanation: Defines the canonical molecular functions of ATRX that are lost in ATR-X syndrome.
  - reference: PMID:37190157
    reference_title: "The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "chromatin remodeling protein that primarily promotes the deposit of H3.3 histone \nvariants in the telomere area."
    explanation: Establishes the ATRX/H3.3 chromatin-deposition mechanism underlying the disorder.
pathophysiology:
- name: ATRX chromatin-remodeling loss of function
  description: >
    Hypomorphic ATRX variants disrupt the chromatin-remodeling ATPase activity of ATRX and its
    ADD-domain-mediated recruitment to H3K9me3-marked heterochromatin. With DAXX, ATRX deposits
    the histone variant H3.3 at telomeric and pericentromeric heterochromatin; loss of this
    activity impairs heterochromatin maintenance, transcriptional regulation, and genome
    stability, driving the neurodevelopmental and multisystem manifestations.
  genes:
  - preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: DECREASED
  - preferred_term: Heterochromatin organization
    term:
      id: GO:0070828
      label: heterochromatin organization
    modifier: DECREASED
  - preferred_term: H3.3 nucleosome assembly
    term:
      id: GO:0006334
      label: nucleosome assembly
    modifier: DECREASED
  - preferred_term: Regulation of transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: ABNORMAL
  - preferred_term: DNA repair
    term:
      id: GO:0006281
      label: DNA repair
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37171606
    reference_title: "A new mouse model of ATR-X syndrome carrying a common patient mutation exhibits neurological and morphological defects."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "carrying the most common causative mutation, R246C. \nThis is one of a cluster of missense mutations located in the chromatin-binding \ndomain and disrupts its function."
    explanation: >
      The patient-mutation knock-in mouse demonstrates that the common R246C variant lies in the
      chromatin-binding domain and disrupts its function, the core molecular lesion of ATR-X syndrome.
  - reference: PMID:39479502
    reference_title: "Mutant ATRX: pathogenesis of ATRX syndrome and cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These \nmutations disrupt the organization, subcellular \nlocalization, and transcriptional activity of ATRX, leading to chromosomal \ninstability and affecting interactions with key regulatory proteins such as \nDAXX, EZH2, and TERRA."
    explanation: Establishes that ATRX mutations impair its organization, localization, transcriptional activity, and DAXX interaction, producing chromosomal instability.
  downstream:
  - target: Intellectual disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Distinctive craniofacial features
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Telecanthus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Genital anomalies
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hypospadias
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Alpha-thalassemia with HbH inclusions
    causal_link_type: DIRECT
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Behavioral abnormality
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Congenital heart defect
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Gastrointestinal dysmotility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Gastroesophageal reflux
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Drooling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Skeletal abnormality
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Short stature
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Osteosarcoma
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
genetic:
- name: ATRX pathogenic variants
  notes: >
    ATR-X syndrome is caused by hemizygous pathogenic variants in ATRX (Xq21.1), a member of
    the SWI/SNF family with chromatin-remodeling activity. Missense variants are the most common
    variant type, and the ADD and helicase-like domains are the most frequently affected. Complete
    null alleles are not seen in patients, consistent with embryonic lethality of full ATRX
    deletion in mice; clinical alleles are hypomorphic.
  gene_term:
    preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  evidence:
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "are caused by pathogenic variant in the ATRX gene, a member of the \nswitch/sucrose non-fermentable (SWI-SNF) protein family that exhibits chromatin \nremodeling activity."
    explanation: Identifies ATRX as the causal SWI/SNF chromatin-remodeling gene.
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Missense \nmutation is the most common variation \ntype. The ADD and helicase-like domains are the most frequently affected \ndomains."
    explanation: Establishes the variant-type spectrum and most frequently affected protein domains.
  - reference: PMID:37171606
    reference_title: "A new mouse model of ATR-X syndrome carrying a common patient mutation exhibits neurological and morphological defects."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Given that null \nalleles are not found in patients"
    explanation: Confirms that pathogenic ATRX alleles in patients are hypomorphic rather than null.
phenotypes:
- name: Intellectual disability
  description: >
    Mild-to-profound intellectual disability / developmental delay is a near-universal,
    defining feature of ATR-X syndrome.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mild-to-profound \ndevelopmental delay / intellectual disability (DD/ID)."
    explanation: GeneReviews lists mild-to-profound DD/ID as a core feature.
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mild-to-profound \nintellectual disability"
    explanation: >
      Wang et al. 2024 lists mild-to-profound intellectual disability among the core
      manifestations; in their cohort (Table 1, attached image) intellectual disability was
      present in 43/43 patients (100%), supporting a VERY_FREQUENT frequency band.
    images:
    - ATRX_Syndrome-deep-research-falcon_artifacts/image-1.png
- name: Distinctive craniofacial features
  description: >
    Characteristic facial features include small head circumference, telecanthus or widely
    spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip, with
    coarsening of facial features over time.
  phenotype_term:
    preferred_term: Distinctive (hypotonic) facies
    term:
      id: HP:0001999
      label: Abnormal facial shape
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial abnormalities include small head circumference, \ntelecanthus or widely spaced eyes, short triangular nose, tented upper lip, and \nthick or everted lower lip with coarsening of the facial features over time."
    explanation: GeneReviews describes the distinctive craniofacial phenotype of ATR-X syndrome.
- name: Telecanthus
  description: >
    Telecanthus (or widely spaced eyes) is part of the characteristic craniofacial pattern.
  phenotype_term:
    preferred_term: Telecanthus
    term:
      id: HP:0000506
      label: Telecanthus
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "telecanthus or widely spaced eyes"
    explanation: GeneReviews lists telecanthus among the craniofacial abnormalities.
- name: Hypotonia
  description: >
    Hypotonia (low muscle tone) is a core feature of the syndrome, reflected in its alternate
    name "hypotonic facies syndrome."
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genital \nanomalies, hypotonia, and mild-to-profound developmental delay / intellectual \ndisability (DD/ID)."
    explanation: GeneReviews lists hypotonia as a characteristic feature.
- name: Genital anomalies
  description: >
    Genital anomalies range from hypospadias and undescended testicles, to severe hypospadias
    and ambiguous genitalia, to normal-appearing female external genitalia, despite a normal
    46,XY karyotype.
  phenotype_term:
    preferred_term: Abnormal male external genitalia morphology
    term:
      id: HP:0000032
      label: Abnormal male external genitalia morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genital anomalies \ncomprise a range from hypospadias and undescended testicles, to severe \nhypospadias and ambiguous genitalia, to normal-appearing female external \ngenitalia."
    explanation: GeneReviews describes the spectrum of genital/genitourinary anomalies in 46,XY males.
- name: Hypospadias
  description: >
    Hypospadias is a recurrent component of the genital anomaly spectrum.
  phenotype_term:
    preferred_term: Hypospadias
    term:
      id: HP:0000047
      label: Hypospadias
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hypospadias and undescended testicles"
    explanation: GeneReviews lists hypospadias among the genital anomalies.
- name: Alpha-thalassemia with HbH inclusions
  description: >
    Alpha-thalassemia is observed in about 75% of affected individuals; it is mild and typically
    does not require treatment. Hemoglobin H (HbH) inclusions in erythrocytes are a hematologic
    hallmark.
  phenotype_term:
    preferred_term: HbH hemoglobin
    term:
      id: HP:0011903
      label: HbH hemoglobin
  frequency: FREQUENT
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alpha-thalassemia, observed in about 75% of affected individuals, is \nmild and typically does not require treatment."
    explanation: >
      GeneReviews documents alpha-thalassemia in about 75% of individuals, supporting a FREQUENT
      band (the Wang et al. 2024 cohort reported 18/43, 41.86%, confirming it is common but not
      universal).
- name: Seizures
  description: >
    Seizures occur in a subset of patients and are reported as more prevalent with frameshift
    than missense variants.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DD/ID, seizures, gastrointestinal \nmanifestations and feeding difficulties"
    explanation: GeneReviews lists seizures among the manifestations managed in ATR-X syndrome.
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epilepsy, congenital heart disease, urogenital defect, acoustic defect, \nand optical defect are more prevalent in patients with frameshift mutations \ncompared to those with missense mutations."
    explanation: >
      Wang et al. 2024 reports epilepsy among recurrent manifestations (10/43, 23.26% in their
      cohort), more prevalent with frameshift than missense variants; supports an OCCASIONAL band.
- name: Behavioral abnormality
  description: >
    Autistic behavior and other behavioral problems are recurrent neurobehavioral features.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "typical facial \nabnormalities, urogenital defect, behavior problems, and optical nerve \ndysplasia."
    explanation: >
      Wang et al. 2024 reports behavior problems in the proband; autism/behavioral problems were
      a recurrent feature in their cohort (19/43, 44.19%).
- name: Congenital heart defect
  description: >
    Congenital heart disease is an associated but less frequent congenital manifestation.
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:39363269
    reference_title: "Identification of a Novel Frameshift variant of the ATRX gene: a Case Report and Review of the genotype-phenotype relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epilepsy, congenital heart disease, urogenital defect, acoustic defect, \nand optical defect are more prevalent in patients with frameshift mutations \ncompared to those with missense mutations."
    explanation: >
      Wang et al. 2024 reports congenital heart disease among recurrent manifestations (8/43,
      18.60% in their cohort), supporting an OCCASIONAL frequency band.
- name: Gastrointestinal dysmotility
  description: >
    Gastrointestinal involvement can be clinically dominant, including chronic gastroesophageal
    reflux, drooling, constipation, abdominal distension, feeding difficulties, and severe
    complications such as intestinal malrotation/volvulus.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  frequency: FREQUENT
  evidence:
  - reference: PMID:39741769
    reference_title: "Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "significant gastrointestinal (GI) \ncomplications, such as abdominal distension, chronic constipation, feeding \ndifficulties, gastroesophageal reflux"
    explanation: Comisi et al. 2024 documents the GI complication spectrum, including chronic constipation.
- name: Gastroesophageal reflux
  description: >
    Chronic gastroesophageal reflux is among the most common GI manifestations.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:39741769
    reference_title: "Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gastroesophageal reflux, and mild-to-moderate anemia secondary to \nalpha-thalassemia."
    explanation: Comisi et al. 2024 lists gastroesophageal reflux among the GI complications.
- name: Drooling
  description: >
    Excessive drooling is a recognized manifestation managed in ATR-X syndrome.
  phenotype_term:
    preferred_term: Drooling
    term:
      id: HP:0002307
      label: Drooling
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "excessive drooling, and genital \nanomalies are managed per standard of care."
    explanation: GeneReviews lists excessive drooling among the manifestations managed in ATR-X syndrome.
- name: Skeletal abnormality
  description: >
    Skeletal and musculoskeletal abnormalities are characteristic features of ATR-X syndrome.
  phenotype_term:
    preferred_term: Skeletal/musculoskeletal abnormality
    term:
      id: HP:0011842
      label: Abnormal skeletal morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:36292677
    reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characteristic facial dysmorphism, hypotonia, gastrointestinal, \nskeletal, urogenital, and hematological anomalies as characteristic features."
    explanation: Vaisfeld et al. 2022 lists skeletal anomalies among the characteristic features.
- name: Short stature
  description: >
    Short stature / reduced body size is reported among the musculoskeletal features and is
    recapitulated in the patient-mutation knock-in mouse model.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:37171606
    reference_title: "A new mouse model of ATR-X syndrome carrying a common patient mutation exhibits neurological and morphological defects."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Clinical features \nalso include facial dysmorphism, microcephaly, short stature, musculoskeletal \ndefects and genital abnormalities."
    explanation: Tillotson et al. 2023, a patient-mutation knock-in mouse model of ATR-X syndrome, lists short stature among the human clinical features the model recapitulates.
- name: Microcephaly
  description: >
    Small head circumference / microcephaly is part of the craniofacial phenotype of
    ATR-X syndrome.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "small head circumference"
    explanation: The ATR-X GeneReviews lists small head circumference (microcephaly) among the craniofacial abnormalities of the syndrome.
- name: Osteosarcoma
  description: >
    Osteosarcoma has been reported in a small number of males with germline ATRX pathogenic
    variants, representing a rare neoplastic complication of the syndrome.
  phenotype_term:
    preferred_term: Osteosarcoma
    term:
      id: HP:0002669
      label: Osteosarcoma
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Osteosarcoma has been reported in"
    explanation: The ATR-X GeneReviews reports osteosarcoma in a few males with germline ATRX pathogenic variants.
treatments:
- name: Genetic counseling
  description: >
    ATR-X syndrome is inherited in an X-linked manner; genetic counseling addresses carrier
    testing for at-risk females, prenatal testing, and preimplantation genetic testing once the
    family ATRX variant is identified.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "carrier testing for at-risk females, prenatal testing for pregnancies at \nincreased risk, and preimplantation genetic testing are possible."
    explanation: GeneReviews recommends genetic counseling and family-based genetic testing options.
- name: Supportive and symptom-directed care
  description: >
    No disease-modifying therapy is established; management is supportive and phenotype-driven,
    including standard-of-care management of DD/ID, seizures, gastrointestinal manifestations and
    feeding difficulties, excessive drooling, and genital anomalies.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DD/ID, seizures, gastrointestinal \nmanifestations and feeding difficulties, excessive drooling, and genital \nanomalies are managed per standard of care."
    explanation: GeneReviews describes supportive, standard-of-care management of manifestations.
- name: Pyridostigmine for gastrointestinal dysmotility
  description: >
    Pyridostigmine, an acetylcholinesterase inhibitor / gastrointestinal motility agent, has been
    used off-label for severe GI dysmotility in ATR-X syndrome. In a reported case, sustained
    treatment led to full resolution of gastrointestinal symptoms, with favorable pediatric
    tolerability.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyridostigmine
      term:
        id: CHEBI:8665
        label: Pyridostigmine
  evidence:
  - reference: PMID:39741769
    reference_title: "Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a patient with ATR-X syndrome suffering from \ngastrointestinal dysmotility and highlight the beneficial effects of \npyridostigmine."
    explanation: Comisi et al. 2024 reports pyridostigmine as a therapeutic option for GI dysmotility in ATR-X syndrome.
📚

References & Deep Research

References

1
PMID:20301622
Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 39 citations 2026-06-04T00:02:30.672658

1. Disease Information

1.1 Concise overview (current understanding)

ATR-X syndrome is a rare, primarily male-affecting X-linked neurodevelopmental disorder caused by hypomorphic germline variants in ATRX, characterized by intellectual disability (ID) often accompanied by alpha-thalassemia and multi-system congenital anomalies (facial dysmorphism, hypotonia, skeletal and urogenital abnormalities, and hematologic findings). (tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2, pang2023thechromatinremodeler pages 1-2)

1.2 Key identifiers and nomenclature

A structured summary of the identifiers and naming used in the retrieved literature is provided below.

Disease name Major synonyms / alternative names OMIM number(s) Inheritance Estimated prevalence Orphanet / MONDO / MeSH / ICD status in retrieved full text Key references (year, URL)
ATR-X syndrome ATRX syndrome; alpha-thalassemia/intellectual disability, X-linked; alpha-thalassemia X-linked intellectual disability syndrome; alpha-thalassemia mental retardation syndrome, X-linked OMIM: 301040 X-linked; primarily affects hemizygous males, with female carriers often minimally affected due to skewed X-inactivation (tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2) Rare; estimated at ~1/30,000-1/40,000 male newborns in one 2024 review/case synthesis; worldwide prevalence otherwise described as unknown (wang2024identificationofa pages 1-2, maganaacosta2025atrxfrom pages 13-13) Orphanet: not found in retrieved full text for this disease entry; MONDO: Not found in retrieved full text; MeSH: Not found in retrieved full text; ICD: Not found in retrieved full text Wang et al. 2024, https://doi.org/10.1186/s12887-024-05088-0; Tillotson et al. 2023, https://doi.org/10.1101/2023.01.25.525394; Yuan et al. 2024, https://doi.org/10.3389/fmolb.2024.1434398 (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2)
ATRX-related disorder label noted in literature X-linked intellectual disability-hypotonic facies syndrome-1 (MRXHF1); ATRX gene-related syndromes OMIM: 309580 (MRXHF1, related ATRX-associated disorder noted in 2024 review/case report) X-linked (wang2024identificationofa pages 1-2) Not separately estimated in retrieved full text Orphanet: Not found in retrieved full text; MONDO: Not found in retrieved full text; MeSH: Not found in retrieved full text; ICD: Not found in retrieved full text Wang et al. 2024, https://doi.org/10.1186/s12887-024-05088-0 (wang2024identificationofa pages 1-2)

Table: This table summarizes the nomenclature and core identifiers for ATR-X syndrome from the retrieved evidence, including synonyms, OMIM entries, inheritance, prevalence estimates, and publication sources. It also flags identifier systems that were not explicitly available in the retrieved full text.

  • OMIM: ATR-X syndrome is explicitly linked to OMIM 301040 in multiple retrieved sources. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)
  • Related ATRX disorder label in retrieved text: MRXHF1 (X-linked intellectual disability-hypotonic facies syndrome-1) is referenced as an ATRX-related disorder with OMIM 309580. (wang2024identificationofa pages 1-2)
  • Orphanet/ICD/MeSH/MONDO: Not explicitly present in the retrieved full text snippets and therefore not reportable here as evidence-backed codes. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)

1.3 Synonyms / alternative names

Commonly used synonyms in the retrieved literature include: “ATR-X syndrome”, “ATRX syndrome”, “alpha-thalassemia/intellectual disability, X-linked”, and “alpha-thalassemia X-linked intellectual disability”. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)

1.4 Evidence source type

The information synthesized here is derived from (i) aggregated disease-level reviews and cohorts, and (ii) individual case reports with literature review, as well as model organism work (mouse). (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4, lupu2024pyridostigmineasa pages 2-3)

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic variants in ATRX (Xq21.1), encoding a SNF2-family chromatin remodeling protein with key functional domains (ADD and helicase/ATPase-like domains). (wang2024identificationofa pages 1-2, pang2023thechromatinremodeler pages 1-2)

Variant spectrum and general rule: In ATR-X syndrome, alleles are typically hypomorphic (commonly missense; also small in-frame/other changes), and complete null alleles are not typically seen clinically, consistent with embryonic lethality when ATRX is fully deleted in mouse. (tillotson2023anewmouse pages 1-4, maganaacosta2025atrxfrom pages 13-13)

2.2 Risk factors

For an X-linked Mendelian disorder, the principal “risk factors” are genetic: - Sex (male/hemizygous): male predominance is expected because hemizygous males are typically affected, while female carriers are often less affected, consistent with X-inactivation effects. (yuan2024mutantatrxpathogenesis pages 1-2, maganaacosta2025atrxfrom pages 13-13) - Family history / carrier mother: implied by X-linked inheritance (not quantified in retrieved snippets). (maganaacosta2025atrxfrom pages 13-13)

2.3 Protective factors

No genetic or environmental protective factors were identified in the retrieved full text.

2.4 Gene–environment interactions

No clear gene–environment interaction evidence specific to ATR-X syndrome was found in the retrieved full text.

3. Phenotypes

3.1 Phenotype spectrum and key clinical manifestations

Core features repeatedly described include: - Intellectual disability / developmental delay (universal in many cohorts) - Alpha-thalassemia / HbH features (common but not universal) - Craniofacial dysmorphism - Hypotonia - Urogenital anomalies - Skeletal abnormalities - Gastrointestinal complications (can be severe)

These are summarized across recent reviews and patient-based syntheses. (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2)

3.2 Phenotype frequencies (recent quantitative data)

Recent cohort-level percentages extracted from a 2024 case + systematic literature synthesis are summarized below.

Phenotype HPO term suggestion Frequency / notes Evidence / source
Intellectual disability HP:0001249 Intellectual disability 100% (reported as 43/43 in the reviewed cohort); described as universal in the summarized ATRX cohort. Wang et al. 2024 review/case synthesis; cohort percentages extracted from text discussing genotype–phenotype relationships (wang2024identificationofa pages 7-8)
Alpha-thalassemia / HbH inclusion HP:0001927 Abnormal hemoglobin; HP:0005523 Hemoglobin H inclusion bodies; HP:0001878 Hemolytic anemia 41.86% overall (18/43) in the summarized cohort; alpha-thalassemia is common but not universal, so absence does not exclude ATR-X syndrome. Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8)
Autism / behavioral problems HP:0000729 Autistic behavior; HP:0000708 Behavioral abnormality 44.19% overall (19/43); reported as a recurrent neurobehavioral feature. Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8)
Epilepsy HP:0001250 Seizure 23.26% overall (10/43); reported among recurrent neurologic manifestations and noted as more prevalent in frameshift variants than missense variants in the broader review. Wang et al. 2024 phenotype summary and genotype–phenotype discussion (wang2024identificationofa pages 7-8, wang2024identificationofa pages 1-2)
Congenital heart defects HP:0001627 Abnormal heart morphology; HP:0001644 Congenital heart defect 18.60% overall (8/43); reported as an associated but less frequent congenital manifestation. Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8)
Mutation-type/domain stratification note Not applicable Full phenotype distributions stratified by mutation type are in Table 1, and genotype–phenotype relationships by affected protein domain are in Table 2 of Wang et al. 2024; these tables were identified from the page images. Table-image extraction identifying Table 1 and Table 2 as the key frequency/genotype–phenotype tables (wang2024identificationofa media 3e3625e3, wang2024identificationofa media bc05e6ce)

Table: This table summarizes key clinical features of ATR-X syndrome with cohort frequencies reported in Wang et al. 2024. It is useful for rapid phenotype curation and notes where the full mutation-type and domain-specific distributions can be found.

Additionally, Table 1 and Table 2 with expanded phenotype frequencies stratified by mutation type and protein domain were identified in the Wang et al. 2024 paper images. (wang2024identificationofa media 3e3625e3, wang2024identificationofa media bc05e6ce)

3.3 Gastrointestinal phenotypes and quality-of-life impact

Gastrointestinal involvement can be clinically dominant and life-threatening in some individuals. A 2024 ATR-X case report and literature review emphasized that ATR-X patients may have gastroesophageal and motility manifestations “most commonly gastroesophageal issues, including chronic gastroesophageal reflux (GER), drooling and constipation.” (lupu2024pyridostigmineasa pages 2-3)

Severe GI complications discussed in this review include intestinal malrotation/volvulus and recurrent bowel volvulus; the review notes such issues can contribute to major morbidity and even mortality. (lupu2024pyridostigmineasa pages 2-3)

3.4 Suggested HPO terms (examples)

Examples are included in the phenotype-frequency artifact and include: - Intellectual disability (HP:0001249) - Seizures (HP:0001250) - Congenital heart defect (HP:0001644) - Autistic behavior (HP:0000729) - HbH inclusion bodies (HP:0005523)

(See | Phenotype | HPO term suggestion | Frequency / notes | Evidence / source | |---|---|---|---| | Intellectual disability | HP:0001249 Intellectual disability | 100% (reported as 43/43 in the reviewed cohort); described as universal in the summarized ATRX cohort. | Wang et al. 2024 review/case synthesis; cohort percentages extracted from text discussing genotype–phenotype relationships (wang2024identificationofa pages 7-8) | | Alpha-thalassemia / HbH inclusion | HP:0001927 Abnormal hemoglobin; HP:0005523 Hemoglobin H inclusion bodies; HP:0001878 Hemolytic anemia | 41.86% overall (18/43) in the summarized cohort; alpha-thalassemia is common but not universal, so absence does not exclude ATR-X syndrome. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Autism / behavioral problems | HP:0000729 Autistic behavior; HP:0000708 Behavioral abnormality | 44.19% overall (19/43); reported as a recurrent neurobehavioral feature. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Epilepsy | HP:0001250 Seizure | 23.26% overall (10/43); reported among recurrent neurologic manifestations and noted as more prevalent in frameshift variants than missense variants in the broader review. | Wang et al. 2024 phenotype summary and genotype–phenotype discussion (wang2024identificationofa pages 7-8, wang2024identificationofa pages 1-2) | | Congenital heart defects | HP:0001627 Abnormal heart morphology; HP:0001644 Congenital heart defect | 18.60% overall (8/43); reported as an associated but less frequent congenital manifestation. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Mutation-type/domain stratification note | Not applicable | Full phenotype distributions stratified by mutation type are in Table 1, and genotype–phenotype relationships by affected protein domain are in Table 2 of Wang et al. 2024; these tables were identified from the page images. | Table-image extraction identifying Table 1 and Table 2 as the key frequency/genotype–phenotype tables (wang2024identificationofa media 3e3625e3, wang2024identificationofa media bc05e6ce) |

Table: This table summarizes key clinical features of ATR-X syndrome with cohort frequencies reported in Wang et al. 2024. It is useful for rapid phenotype curation and notes where the full mutation-type and domain-specific distributions can be found..)

4. Genetic / Molecular Information

4.1 Causal gene

  • ATRX (Xq21.1) is the causal gene for ATR-X syndrome (OMIM 301040). (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4)

4.2 Pathogenic variant classes and genotype–phenotype notes

A 2024 case report with literature synthesis notes that missense variants are most common overall and that the ADD and helicase-like domains are frequently affected; it also reports mutation-type associations (e.g., frameshift variants showing higher prevalence of epilepsy, congenital heart disease, urogenital, acoustic, and optical defects compared with missense). (wang2024identificationofa pages 1-2)

4.3 Functional consequences and molecular functions (current understanding)

ATRX is described as a chromatin-remodeling ATPase involved in transcriptional regulation, DNA damage repair, and heterochromatin maintenance. (tillotson2023anewmouse pages 1-4)

Mechanistic reviews emphasize ATRX roles in chromatin remodeling and genomic integrity, including cooperating with DAXX to deposit histone variant H3.3 at repetitive regions (e.g., telomeric/pericentromeric heterochromatin). (pang2023thechromatinremodeler pages 1-2, vaisfeld2022phenotypicspectrumand pages 1-2)

4.4 Epigenetic information and episignatures

DNA methylation episignatures are increasingly used as functional biomarkers in neurodevelopmental Mendelian disorders; ATRX has a published episignature that has been independently evaluated and shown high diagnostic performance (see Diagnostics section). (husson2024episignaturesinpractice pages 1-2, trajkova2024dnamethylationanalysis pages 1-2)

5. Environmental Information

No specific environmental toxins, lifestyle factors, or infectious triggers were identified in the retrieved full text as contributing causes for ATR-X syndrome (a genetic disorder).

6. Mechanism / Pathophysiology

6.1 Mechanistic chain (high-level)

ATRX hypomorphic loss → altered recruitment/function of a chromatin remodeling ATPase at heterochromatin and other genomic regions → impaired regulation of transcription, heterochromatin maintenance, and genome stability/replication stress responses → neurodevelopmental defects (ID, microcephaly-like phenotypes), multi-system congenital anomalies, and hematologic dysregulation consistent with alpha-thalassemia in many patients. (tillotson2023anewmouse pages 1-4, tillotson2023anewmouse pages 16-22, pang2023thechromatinremodeler pages 1-2)

6.2 Cell and molecular processes implicated (evidence-backed themes)

  • Chromatin remodeling and transcriptional regulation: ATRX is repeatedly described as a chromatin remodeler/transcriptional regulator. (pang2023thechromatinremodeler pages 1-2, tillotson2023anewmouse pages 1-4)
  • DNA damage/replication stress responses: ATRX is described as involved in DNA damage repair; the patient-mutation knock-in mouse paper also frames ATRX in this functional context. (tillotson2023anewmouse pages 1-4)
  • Heterochromatin maintenance / recruitment via histone marks: the knock-in mouse model highlights disrupted heterochromatin recruitment mediated by ADD-domain binding to H3K9me3, stating “This recruitment is severely disrupted by the R245C mutation.” (tillotson2023anewmouse pages 16-22)

6.3 Suggested ontology terms

  • GO (biological process; examples): chromatin remodeling; DNA repair; regulation of transcription; response to replication stress. (tillotson2023anewmouse pages 1-4, tillotson2023anewmouse pages 16-22)
  • GO (cellular component; examples): heterochromatin; nucleus. (tillotson2023anewmouse pages 16-22)
  • Cell Ontology (CL; examples): neurodevelopmental relevance suggests neural progenitors/neurons; the mouse model includes hippocampal neuron phenotypes (neurite/dendrite changes). (tillotson2023anewmouse pages 13-16, tillotson2023anewmouse pages 10-13)

7. Anatomical Structures Affected

Evidence supports multi-system involvement: - Central nervous system: neurodevelopmental phenotype; mouse knock-in shows reduced brain weight and cerebellar/corpus callosum structural changes. (tillotson2023anewmouse pages 10-13) - Hematopoietic system: alpha-thalassemia is a defining feature for many patients (not universal). (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 7-8) - Gastrointestinal tract: severe dysmotility/GER/constipation and complications (malrotation/volvulus) reported. (lupu2024pyridostigmineasa pages 2-3) - Urogenital system: genital abnormalities and urogenital defects are part of the typical clinical description. (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4)

8. Temporal Development

Onset is typically congenital/early childhood consistent with a neurodevelopmental disorder; the knock-in mouse model is framed as developmental rather than degenerative (normal head circumference at birth but later differences in brain size/structure). (tillotson2023anewmouse pages 10-13)

9. Inheritance and Population

9.1 Inheritance

ATR-X syndrome is X-linked and affects “primarily… hemizygous males,” with females often being carriers due to X-inactivation effects. (tillotson2023anewmouse pages 1-4, maganaacosta2025atrxfrom pages 13-13)

9.2 Epidemiology

A 2024 review/case synthesis reports the condition as rare with an estimated prevalence of approximately 1/30,000–1/40,000 male newborns. (wang2024identificationofa pages 1-2)

10. Diagnostics

10.1 Genetic testing (current practice)

WES/NGS is used to identify ATRX variants in suspected cases; one 2024 report diagnosed an ATRX-related phenotype by whole-exome sequencing and applied ACMG criteria for classification. (wang2024identificationofa pages 1-2)

10.2 DNA methylation episignatures (recent developments; 2023–2024 prioritized)

Recent work supports using genome-wide DNA methylation “episignatures” as diagnostic/variant-interpretation tools in neurodevelopmental disorders: - A 2024 independent evaluation of published episignatures reported 100% specificity of the procedure and that the ATRX episignature displayed 100% sensitivity in that dataset. (husson2024episignaturesinpractice pages 1-2) - A 2024 clinical study applying episignatures in neurodevelopmental disorders reported the expected episignature in 53/59 (90%) validation cases and identified an ATRX-associated case via methylation profiling in the test cohort. (trajkova2024dnamethylationanalysis pages 1-2)

10.3 Long-read sequencing integrated genomics + methylation (emerging implementation)

Nanopore long-read sequencing approaches can simultaneously call genetic variants and derive methylation signatures: - A 2024 preprint reported classifier-recognized episignature assignment in 17/20 patients and classification of all healthy controls as controls; the paper also illustrates how episignature and segregation data can support benign interpretation of an ATRX VUS in a complex case. (geysens2024nanoporesequencingbasedepisignature pages 11-14) - A 2025 long-read methylome study included ATR-X syndrome cases and extracted ATR-X-specific long-read DNA methylation signatures as alternatives to array-based signatures. (mizuguchi2025diagnosticutilityof pages 1-2)

A structured diagnostic summary is provided below.

Test modality Purpose Key findings / performance Real-world implementation notes Key references with URL / date
Whole-exome sequencing (WES) / broader NGS Detect germline pathogenic ATRX variants in suspected ATR-X syndrome or related ATRX-associated neurodevelopmental phenotypes WES identified a novel frameshift ATRX variant in a child with ATRX-related disease; the 2024 review/case synthesis notes ATR-X syndrome and MRXHF1 are caused by ATRX pathogenic variants, with missense variants most common overall and ADD/helicase domains frequently affected (wang2024identificationofa pages 1-2) Practical first-line molecular test in rare disease workups; useful when phenotype includes intellectual disability, hypotonia, craniofacial features, genital anomalies, GI disease, seizures, or anemia/alpha-thalassemia; variants are typically classified with ACMG criteria and may require segregation/orthogonal confirmation (wang2024identificationofa pages 1-2) Wang et al., BMC Pediatrics (Oct 2024), https://doi.org/10.1186/s12887-024-05088-0 (wang2024identificationofa pages 1-2)
Whole-genome sequencing (WGS) / structural-variant-capable sequencing Detect SNVs plus structural or intragenic ATRX variants that may be missed or only partially resolved by targeted approaches Long-read WGS-based workflows can simultaneously identify single-nucleotide and structural variants while also deriving methylation data; automated nanopore calling identified 18/19 SNVs in one developmental-disorders cohort, with one low-level mosaic variant requiring manual review (geysens2024nanoporesequencingbasedepisignature pages 11-14) Particularly relevant when prior exome/panel testing is negative, when a CNV/deletion is suspected, or when integrated genomic + epigenomic resolution is needed for interpretation; still emerging rather than universal standard of care for ATRX syndrome (geysens2024nanoporesequencingbasedepisignature pages 11-14, mizuguchi2025diagnosticutilityof pages 1-2) Geysens et al., medRxiv (Apr 2024), https://doi.org/10.1101/2024.04.19.24305959; Mizuguchi et al., Clinical Epigenetics (Feb 2025), https://doi.org/10.1186/s13148-025-01832-0 (geysens2024nanoporesequencingbasedepisignature pages 11-14, mizuguchi2025diagnosticutilityof pages 1-2)
DNA methylation episignature testing (EpiSign / array-based episignature workflow) Functional support for diagnosis and variant interpretation, especially VUS resolution in ATRX-related neurodevelopmental disease In a 97-case NDD series, expected episignatures were observed in 53/59 validation cases (90% overall), and ATRX-associated methylation profiling helped identify an ATRX-related diagnostic case in the test cohort (trajkova2024dnamethylationanalysis pages 1-2) Useful as a second-line functional assay after sequencing when phenotype is compatible but variant classification remains uncertain; can complement genomic findings and improve interpretation of ATRX deletions or uncertain variants (trajkova2024dnamethylationanalysis pages 1-2) Trajkova et al., Human Genetics and Genomics Advances (Jul 2024), https://doi.org/10.1016/j.xhgg.2024.100309 (trajkova2024dnamethylationanalysis pages 1-2)
Independent episignature validation for ATRX signature Assess diagnostic accuracy / readiness for clinical use of published ATRX episignatures Independent validation across ten NDD episignatures reported 100% specificity overall for the procedure, and the ATRX episignature showed 100% sensitivity in that dataset (husson2024episignaturesinpractice pages 1-2) Supports real-world diagnostic confidence for ATRX methylation testing relative to several less robust signatures; authors still caution that broader validation and clear validity boundaries remain important before overgeneralization (husson2024episignaturesinpractice pages 1-2) Husson et al., European Journal of Human Genetics (Oct 2024), https://doi.org/10.1038/s41431-023-01474-x (husson2024episignaturesinpractice pages 1-2)
Nanopore long-read sequencing with integrated episignature detection Simultaneous genetic and epigenetic testing in a single assay In a proof-of-concept developmental-disorders cohort, SVM classifiers recognized an episignature and assigned the correct disease in 17/20 patients, while all healthy controls were classified as controls; the approach also showed how ATRX episignature information can help classify an ATRX variant as benign in a complex case (geysens2024nanoporesequencingbasedepisignature pages 11-14) Consolidates what is often a multi-step workflow (variant detection, CNV/SV analysis, methylation profiling, and in some settings X-inactivation assessment) into one platform; promising for specialized clinical genetics laboratories, but currently best viewed as advanced/early implementation rather than routine everywhere (geysens2024nanoporesequencingbasedepisignature pages 11-14) Geysens et al., medRxiv (Apr 2024), https://doi.org/10.1101/2024.04.19.24305959 (geysens2024nanoporesequencingbasedepisignature pages 11-14)
Nanopore long-read methylome profiling specifically including ATR-X syndrome cases Define long-read DNA methylation signatures unique to ATR-X syndrome and potentially raise diagnostic yield Sequencing of seven ATR-X syndrome cases and 22 controls enabled extraction of ATR-X-specific long-read DNA methylation signatures as alternatives to array-derived episignatures; authors argue simultaneous genetic and epigenetic evaluation may improve discovery and diagnostic yield (mizuguchi2025diagnosticutilityof pages 1-2) Relevant for future integrated diagnostics and for laboratories interested in replacing sequential array + sequencing workflows with one assay; ATRX-specific sensitivity/specificity values were not provided in the retrieved excerpt (mizuguchi2025diagnosticutilityof pages 1-2) Mizuguchi et al., Clinical Epigenetics (Feb 2025), https://doi.org/10.1186/s13148-025-01832-0 (mizuguchi2025diagnosticutilityof pages 1-2)

Table: This table summarizes current diagnostic modalities for ATRX syndrome, spanning standard genomic sequencing and newer DNA methylation episignature approaches. It highlights recent validation and implementation data that are useful for clinical interpretation, especially when variants are uncertain.

11. Outcome / Prognosis

The retrieved evidence is insufficient to provide rigorous survival estimates or life expectancy distributions. However, severe gastrointestinal complications (e.g., malrotation/volvulus) are described as potential causes of severe outcomes including death in some reported contexts, highlighting the need for proactive surveillance and management. (lupu2024pyridostigmineasa pages 2-3)

12. Treatment

12.1 Supportive and symptom-directed management (real-world implementation)

No disease-modifying therapy is established in the retrieved evidence; management is supportive and phenotype-driven.

Gastrointestinal dysmotility: A 2024 case report and review describes pyridostigmine as a potential option and includes a strongly positive single-patient outcome: the patient “was started on oral pyridostigmine… gradually increased… [and] after a year of sustained treatment, his gastrointestinal symptoms fully resolved.” (lupu2024pyridostigmineasa pages 2-3)

The same review summarized safety across pediatric cases: “of the nine patients documented… only one experienced minor side effects (abdominal pain and cramps).” (lupu2024pyridostigmineasa pages 2-3)

12.2 Experimental / emerging therapeutics

A 2025 source summarized exploratory evidence that 5-aminolevulinic acid (5-ALA) may improve cognitive outcomes in a subset of ATR-X patients in a small phase 2 trial (5 participants; 2 responders) and was described as safe/tolerated in that report. (bertocchi2025matrixmetalloproteinase9and pages 57-61)

12.3 MAXO suggestions

A structured treatment-management table with MAXO-style action concepts is provided below.

Intervention Indication/phenotype Dosing Outcome Evidence type MAXO suggestion References
Pyridostigmine ATR-X syndrome with gastrointestinal dysmotility: chronic constipation, abdominal distension, gastroparesis, reflux/feeding difficulty Index ATR-X case: oral 30 mg/day (1.6 mg/kg/day) increased to 60 mg/day (3.2 mg/kg/day) Symptom improvement reported; after 1 year of sustained treatment, gastrointestinal symptoms fully resolved Human clinical case report + literature review MAXO: gastrointestinal motility agent therapy; cholinesterase inhibitor therapy; constipation management Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 2-3, lupu2024pyridostigmineasa pages 1-2)
Pyridostigmine Pediatric GI dysmotility in ATR-X and related severe dysmotility reports Enteral 0.5 mg/kg twice daily, titrated to 1 mg/kg twice daily Clinical improvement; improvement corroborated by abdominal X-ray in reported pediatric use Human clinical literature summarized in review MAXO: gastrointestinal motility agent therapy Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 3-4)
Neostigmine followed by pyridostigmine Severe GI dysmotility/intestinal pseudo-obstructive presentations in pediatric literature reviewed with relevance to ATR-X GI management IV neostigmine 0.5 mg in 50 mL NS at 0.5 mg/hr for 10 days, then oral pyridostigmine 180 mg/day or 7 mg/kg/day Reduced hospital length of stay and reduced dependence on parenteral nutrition; no side effects reported in these reviewed cases Human clinical literature summarized in review MAXO: acetylcholinesterase inhibitor therapy; intestinal pseudo-obstruction management Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 3-4)
Supportive laxative therapy Constipation/dysmotility in ATR-X syndrome Senna, sodium picosulfate, docusate sodium (dose not specified) No definitive effect in reported ATR-X case prior to pyridostigmine escalation Human clinical case report MAXO: laxative therapy; constipation management Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 3-4)
Surgical/enteral supportive intervention Severe gastroesophageal and nutritional complications in ATR-X syndrome Laparoscopic anterior gastropexy plus button PEG-J (dose not applicable) Reported improvement in nutrition and quality of life in literature summarized by review Human clinical literature summarized in review MAXO: gastrostomy tube placement; gastropexy; enteral nutrition support Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 2-3)
Pyridostigmine safety summary Pediatric GI dysmotility treatment safety Across nine documented pediatric cases in the review; variable dosing Only one patient had minor adverse events (abdominal pain/cramps); otherwise favorable tolerability Human literature review MAXO: adverse event monitoring during cholinesterase inhibitor therapy Lupu et al. 2024, Front Pediatr, published Dec 2024, https://doi.org/10.3389/fped.2024.1460658 (lupu2024pyridostigmineasa pages 2-3, lupu2024pyridostigmineasa pages 3-4)
5-Aminolevulinic acid (5-ALA) Exploratory treatment for cognitive dysfunction in ATR-X syndrome 24-week phase 2 exploratory trial; exact dose not provided in retrieved evidence 5 patients enrolled; 2/5 showed cognitive improvement; reported as safe and well tolerated; responders had higher blood 5-ALA/PpIX concentrations Early human clinical trial + preclinical rationale MAXO: developmental disability treatment; experimental metabolic therapy; cognitive symptom management Evidence summarized in 2025 review citing phase 2 trial data (bertocchi2025matrixmetalloproteinase9and pages 57-61)

Table: This table summarizes reported management evidence for ATR-X syndrome, emphasizing gastrointestinal dysmotility interventions and the exploratory 5-ALA cognitive trial. It is useful for distinguishing supportive care from early experimental therapy and for mapping interventions to MAXO-style treatment concepts.

13. Prevention

Primary prevention is not applicable for a monogenic X-linked condition in the usual public health sense; prevention focuses on: - Genetic counseling for at-risk families (carrier testing, reproductive counseling) - Prenatal/preimplantation genetic testing where appropriate and locally available

The retrieved texts emphasize that X-linked inheritance and skewed X-inactivation in females complicate presentation and interpretation, reinforcing the need for genetics-guided counseling. (maganaacosta2025atrxfrom pages 13-13, geysens2024nanoporesequencingbasedepisignature pages 11-14)

14. Other Species / Natural Disease

No naturally occurring veterinary ATRX syndrome analogs were identified in the retrieved full text.

15. Model Organisms

15.1 Mouse model (patient-mutation knock-in; key recent development)

A patient-relevant knock-in mouse model was generated carrying the common patient mutation (R246C; modeled as AtrxR245C/y in mice). The authors state it is “the first patient mutation knock-in model of ATR-X syndrome, carrying the most common patient mutation, R246C,” and report that the mice “recapitulate several aspects of the patient disorder, including craniofacial defects, microcephaly and impaired neurological function.” (tillotson2023anewmouse pages 1-4)

A key mechanistic observation is that ADD-domain–mediated recruitment to heterochromatin is disrupted; the paper states: “This recruitment is severely disrupted by the R245C mutation.” (tillotson2023anewmouse pages 16-22)

15.2 Model limitations

The same mouse model did not recapitulate all hallmark human features, including alpha-thalassemia and genital abnormalities, which is important for translational interpretation. (tillotson2023anewmouse pages 13-16)

Notes on evidence gaps vs. template requirements

  • MONDO/Orphanet/ICD/MeSH codes: not available in the retrieved full text; should be imported from the authoritative databases directly (OMIM/Orphanet/MONDO/MeSH/ICD). (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)
  • Large natural history cohorts and survival statistics: not identified in the retrieved full text; additional registry/natural history sources would be required.

References

  1. (tillotson2023anewmouse pages 1-4): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

  2. (yuan2024mutantatrxpathogenesis pages 1-2): Kejia Yuan, Yan Tang, Zexian Ding, Lei Peng, Jinghua Zeng, Huaying Wu, and Qi Yi. Mutant atrx: pathogenesis of atrx syndrome and cancer. Frontiers in Molecular Biosciences, Oct 2024. URL: https://doi.org/10.3389/fmolb.2024.1434398, doi:10.3389/fmolb.2024.1434398. This article has 7 citations.

  3. (pang2023thechromatinremodeler pages 1-2): Ying Pang, Xu Chen, Tongjie Ji, Meng Cheng, Rui Wang, Chunyu Zhang, Min Liu, Jing Zhang, and Chunlong Zhong. The chromatin remodeler atrx: role and mechanism in biology and cancer. Cancers, 15:2228, Apr 2023. URL: https://doi.org/10.3390/cancers15082228, doi:10.3390/cancers15082228. This article has 51 citations.

  4. (wang2024identificationofa pages 1-2): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

  5. (maganaacosta2025atrxfrom pages 13-13): Mauro Magaña-Acosta and Viviana Valadéz-Graham. atrx : from chromatin remodeling to disease. genesis, Nov 2025. URL: https://doi.org/10.1002/dvg.70031, doi:10.1002/dvg.70031. This article has 1 citations and is from a peer-reviewed journal.

  6. (lupu2024pyridostigmineasa pages 2-3): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

  7. (wang2024identificationofa pages 7-8): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

  8. (wang2024identificationofa media 3e3625e3): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

  9. (wang2024identificationofa media bc05e6ce): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

  10. (vaisfeld2022phenotypicspectrumand pages 1-2): Alessandro Vaisfeld, Sara Taormina, Alessandro Simonati, and Giovanni Neri. Phenotypic spectrum and molecular findings in 17 atr-x syndrome italian patients: some new insights. Genes, 13:1792, Oct 2022. URL: https://doi.org/10.3390/genes13101792, doi:10.3390/genes13101792. This article has 6 citations.

  11. (husson2024episignaturesinpractice pages 1-2): Thomas Husson, François Lecoquierre, Gaël Nicolas, Anne-Claire Richard, Alexandra Afenjar, Séverine AUDEBERT-BELLANGER, Catherine Badens, Frédéric Bilan, Varoona Bizaoui, Anne Boland, Marie-Noelle Bonnet-Dupeyron, Elise Brischoux-Boucher, Céline Bonnet, Marie Bournez, Odile Boute, Perrine Brunelle, Roseline Caumes, Perrine Charles, Nicolas Chassaing, Nicolas Chatron, Benjamin Cogné, Estelle Colin, Valérie Cormier-Daire, Rodolphe Dard, Benjamin Dauriat, Julian Delanne, Jean-François Deleuze, Florence Demurger, Anne-Sophie Denommé-Pichon, Christel Depienne, Anne Dieux Coeslier, Christèle Dubourg, Patrick Edery, salima EL CHEHADEH, Laurence Faivre, Mélanie FRADIN, Aurore Garde, David Geneviève, Brigitte Gilbert-Dussardier, Cyril Goizet, Alice Goldenberg, Evan Gouy, Anne-Marie Guerrot, Anne Guimier, Ines HARZALLAH, Delphine Héron, Bertrand Isidor, Xavier Le Guillou Horn, Boris Keren, Alma Kuechler, Elodie Lacaze, Alinoë Lavillaureix, Daphné Lehalle, Gaetan Lesca, James Lespinasse, Jonathan Levy, Stanislas Lyonnet, Godelieve Morel, Nolwenn Jean Marçais, Sandrine Marlin, Luisa Marsili, Cyril Mignot, Sophie Nambot, Mathilde Nizon, Robert Olaso, Laurent PASQUIER, Laurine Perrin, Florence Petit, Amélie Piton, Fabienne Prieur, Audrey Putoux, Marc Planes, Sylvie Odent, Chloé Quelin, Sylvia Quemener, Mélanie Rama, Marlène RIO, Massimiliano Rossi, Elise Schaefer, Sophie Rondeau, Pascale SAUGIER-VEBER, Thomas Smol, Sabine Sigaudy, Renaud TOURAINE, Frédéric Tran-Mau-Them, Aurélien Trimouille, Clémence Vanlerberghe, Valérie Vantalon, Gabriella Vera, Marie Vincent, Alban Ziegler, Olivier Guillin, Dominique Campion, and Camille Charbonnier. Episignatures in practice: independent evaluation of published episignatures for the molecular diagnostics of ten neurodevelopmental disorders. European Journal of Human Genetics, 32:190-199, Oct 2024. URL: https://doi.org/10.1038/s41431-023-01474-x, doi:10.1038/s41431-023-01474-x. This article has 38 citations and is from a domain leading peer-reviewed journal.

  12. (trajkova2024dnamethylationanalysis pages 1-2): Slavica Trajkova, Jennifer Kerkhof, Matteo Rossi Sebastiano, Lisa Pavinato, Enza Ferrero, Chiara Giovenino, Diana Carli, Eleonora Di Gregorio, Roberta Marinoni, Giorgia Mandrile, Flavia Palermo, Silvia Carestiato, Simona Cardaropoli, Verdiana Pullano, Antonina Rinninella, Elisa Giorgio, Tommaso Pippucci, Paola Dimartino, Jessica Rzasa, Kathleen Rooney, Haley McConkey, Aleksandar Petlichkovski, Barbara Pasini, Elena Sukarova-Angelovska, Christopher M. Campbell, Kay Metcalfe, Sarah Jenkinson, Siddharth Banka, Alessandro Mussa, Giovanni Battista Ferrero, Bekim Sadikovic, and Alfredo Brusco. Dna methylation analysis in patients with neurodevelopmental disorders improves variant interpretation and reveals complexity. Human Genetics and Genomics Advances, 5:100309, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100309, doi:10.1016/j.xhgg.2024.100309. This article has 18 citations and is from a peer-reviewed journal.

  13. (tillotson2023anewmouse pages 16-22): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

  14. (tillotson2023anewmouse pages 13-16): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

  15. (tillotson2023anewmouse pages 10-13): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

  16. (geysens2024nanoporesequencingbasedepisignature pages 11-14): Mathilde Geysens, Benjamin Huremagic, Erika Souche, Jeroen Breckpot, Koenraad Devriendt, Hilde Peeters, Griet Van Buggenhout, Hilde Van Esch, Kris Van Den Bogaert, and Joris Robert Vermeesch. Nanopore sequencing-based episignature detection. MedRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.19.24305959, doi:10.1101/2024.04.19.24305959. This article has 3 citations.

  17. (mizuguchi2025diagnosticutilityof pages 1-2): Takeshi Mizuguchi, Nobuhiko Okamoto, Taiki Hara, Naoto Nishimura, Masamune Sakamoto, Li Fu, Yuri Uchiyama, Naomi Tsuchida, Kohei Hamanaka, Eriko Koshimizu, Atsushi Fujita, Kazuharu Misawa, Kazuhiko Nakabayashi, Satoko Miyatake, and Naomichi Matsumoto. Diagnostic utility of single-locus dna methylation mark in sotos syndrome developed by nanopore sequencing-based episignature. Clinical Epigenetics, Feb 2025. URL: https://doi.org/10.1186/s13148-025-01832-0, doi:10.1186/s13148-025-01832-0. This article has 1 citations and is from a peer-reviewed journal.

  18. (bertocchi2025matrixmetalloproteinase9and pages 57-61): I Bertocchi, F Tempia, E Hoxha, and A Oberto. Matrix metalloproteinase-9 and perineuronal nets as new therapeutic targets for fragile x syndrome (fxs). Unknown journal, 2025.

  19. (lupu2024pyridostigmineasa pages 1-2): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

  20. (lupu2024pyridostigmineasa pages 3-4): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

Artifacts